Patients with locally advanced , recurrent , or metastatic NSCLC who had received at least one and no more than two prior systemic treatment regimens were randomized ( 1:1 ) to a combination of docetaxel ( 75 mg/m intravenous every 21 days ) with or without PX-866 ( 8 mg orally daily ; arms A and B , respectively ) .